Antares Pharma Inc. (ATRS) has jumped in early trading on Tuesday, boosted by positive results for a clinical trial.
Shares of Antares are up $0.28, or 7.8 percent, to $3.88.
The company announced positive results from a human factors usability study for VIBEX Methotrexate, a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis.
For comments and feedback: editorial@rttnews.com